⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Trial of PDL192 in Subjects With Advanced Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Trial of PDL192 in Subjects With Advanced Solid Tumors

Official Title: A Phase 1, Multicenter, Open-Label, Dose Escalation Trial of PDL192 in Subjects With Advanced Solid Tumors

Study ID: NCT00738764

Conditions

Cancer

Interventions

PDL192

Study Description

Brief Summary: This is a phase 1, multicenter, open-label, dose escalation trial of PDL192 in subjects with advanced solid tumors.

Detailed Description: The primary study objective is to determine the maximum tolerated dose of PDL192 in subjects with advanced solid tumors.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Site Reference ID/Investigator# 53365, Scottsdale, Arizona, United States

Site Reference ID/Investigator# 53364, Aurora, Colorado, United States

Contact Details

Name: Mihail Obrocea, MD

Affiliation: Abbott Biotherapeutics Corp.

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: